The role of IFN in the development of NAFLD and NASH
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) and its progressive inflammatory form non-alcoholic steatohepatitis (NASH) are major health challenges due to a significant increase in their incidence and prevalence. While NAFLD is largely benign, the chronic liver inflammation in NASH patients may cause progression to liver cirrhosis and hepatocellular carcinoma. There is an urgent need for a better understanding of the factors, which drive the progression from NAFLD to NASH and how to use this information both to improve diagnostic and to develop new treatment strategies. Increasing evidence points to interferons (IFNs) as key players in NAFLD and particular in the progression to NASH. IFNs crucial role in disease development is supported by both genetic evidence and animal studies. In this review, we describe the involvement of both type I and type III IFNs in the development and progression of NAFLD and NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5
Vijay-Kumar, M., Aitken, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, S., Srinivasan, S., Sitaraman, S. V., Knight, R., Ley, R. E., & Gewirtz, A. T. (2010) · Science · doi:10.1126/science.1179721 · Cited by 2,068
Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110
Speliotes, E. K., Yerges-Armstrong, L. M., Wu, J., Hernaez, R., Kim, L. J., Palmer, C. D., Gudnason, V., Eiriksdottir, G., Garcia, M. E., Launer, L. J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001324 · Cited by 984
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Self-citationA Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827
White, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766
Research works printed but not linked: 79
- Adams, 2007, Nonalcoholic fatty liver disease, Ann. Epidemiol., 17, 863, 10.1016/j.annepidem.2007.05.013 · DOI · Paper page
- Wong, 2015, Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States, Gastroenterology, 148, 547, 10.1053/j.gastro.2014.11.039 · DOI · Paper page
- McCullough, 2004, The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease, Clin. Liver Dis., 8, 521, 10.1016/j.cld.2004.04.004 · DOI · Paper page
- Starley, 2010, Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection, Hepatology, 51, 1820, 10.1002/hep.23594 · DOI · Paper page
- Day, 1998, Steatohepatitis: a tale of two “hits”?, Gastroenterology, 114, 842, 10.1016/S0016-5085(98)70599-2 · DOI · Paper page
- Silverman, 1990, Liver pathology in morbidly obese patients with and without diabetes, Am. J. Gastroenterol., 85, 1349
- Andersen, 1984, The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study, Int. J. Obes., 8, 107
- Poonawala, 2000, Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study, Hepatology, 32, 689, 10.1053/jhep.2000.17894 · DOI · Paper page
- Clark, 2002, Hepatic steatosis and type 2 diabetes mellitus, Curr. Diab. Rep., 2, 210, 10.1007/s11892-002-0085-3 · DOI
- Gupte, 2004, Non-alcoholic steatohepatitis in type 2 diabetes mellitus, J. Gastroenterol. Hepatol., 19, 854, 10.1111/j.1440-1746.2004.03312.x · DOI · Paper page
- Assy, 2000, Fatty infiltration of liver in hyperlipidemic patients, Dig. Dis. Sci., 45, 1929, 10.1023/A:1005661516165 · DOI · Paper page
- Berkowitz, 1964, Metabolic changes associated with obesity before and after weight reduction, JAMA, 187, 399, 10.1001/jama.1964.03060190015003 · DOI
- Donati, 2004, Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance, Gut, 53, 1020, 10.1136/gut.2003.027086 · DOI · Paper page
- Lau, 2015, Gut microbiota: association with NAFLD and metabolic disturbances, Biomed. Res. Int., 2015, 10.1155/2015/979515 · DOI · Paper page
- Valenti, 2010, Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease, Hepatology, 51, 1209, 10.1002/hep.23622 · DOI · Paper page
- Eslam, 2016, Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes, Hepatology, 64, 34, 10.1002/hep.28475 · DOI · Paper page
- Mancina, 2016, The MBOAT7-TMC4 Variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent, Gastroenterology, 150, 1219, 10.1053/j.gastro.2016.01.032 · DOI · Paper page
- Thabet, 2016, MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C, Nat. Commun., 7, 12757, 10.1038/ncomms12757 · DOI · Paper page
- Thabet, 2017, The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B, Hepatology, 65, 1840, 10.1002/hep.29064 · DOI · Paper page
- Petta, 2012, IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease, J. Hepatol., 56, 1356, 10.1016/j.jhep.2012.01.007 · DOI
- Petta, 2017, Interferon lambda 4 rs368234815 TT>deltaG variant is associated with liver damage in patients with nonalcoholic fatty liver disease, Hepatology, 66, 1885, 10.1002/hep.29395 · DOI · Paper page
- Eslam, 2015, Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease, Nat. Commun., 6, 6422, 10.1038/ncomms7422 · DOI · Paper page
- Schreiber, 2017, The molecular basis for differential type I interferon signaling, J. Biol. Chem., 292, 7285, 10.1074/jbc.R116.774562 · DOI · Paper page
- Wack, 2015, Guarding the frontiers: the biology of type III interferons, Nat. Immunol., 16, 802, 10.1038/ni.3212 · DOI · Paper page
- Dickensheets, 2013, Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes, J. Leukoc. Biol., 93, 377, 10.1189/jlb.0812395 · DOI
- Lauber, 2015, Transcriptome analysis reveals a classical interferon signature induced by IFN lambda 4 in human primary cells, Genes Immun., 16, 414, 10.1038/gene.2015.23 · DOI
- Muir, 2014, A randomized Phase 2b Study of peginterferon lambda-1a for the treatment of chronic HCV infection, J. Hepatol., 10.1016/j.jhep.2014.07.022 · DOI
- Hermant, 2014, Interferon-lambda in the context of viral infections: production, response and therapeutic implications, J. Innate Immun., 6, 563, 10.1159/000360084 · DOI
- Durbin, 2013, Interferon induction and function at the mucosal surface, Immunol. Rev., 255, 25, 10.1111/imr.12101 · DOI · Paper page
- Chen, 2016, Evolution of IFN-lambda in tetrapod vertebrates and its functional characterization in green anole lizard (Anolis carolinensis), Dev. Comp. Immunol., 61, 208, 10.1016/j.dci.2016.04.004 · DOI
- Key, 2014, Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4), PLoS Genet., 10, 10.1371/journal.pgen.1004681 · DOI
- Prokunina-Olsson, 2013, A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus, Nat. Genet., 45, 164, 10.1038/ng.2521 · DOI · Paper page
- McFarland, 2014, The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs, Nat. Immunol., 15, 72, 10.1038/ni.2758 · DOI
- Tanaka, 2009, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C, Nat. Genet., 41, 1105, 10.1038/ng.449 · DOI · Paper page
- Suppiah, 2009, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy, Nat. Genet., 41, 10.1038/ng.447 · DOI · Paper page
- Smith, 2011, Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort, Genome Med., 3, 57, 10.1186/gm273 · DOI
- Terczynska-Dyla, 2014, Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes, Nat. Commun., 5, 5699, 10.1038/ncomms6699 · DOI
- Bochud, 2012, IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes, Hepatology, 55, 384, 10.1002/hep.24678 · DOI
- Eslam, 2017, IFN-lambda 3, not IFN-lambda 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis, Nat. Genet., 49, 795, 10.1038/ng.3836 · DOI
- Eslam, 2017, IFN-lambda3, not IFN-lambda4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis, Nat. Genet., 49, 795, 10.1038/ng.3836 · DOI
- Heim, 2014, Innate and adaptive immune responses in HCV infections, J. Hepatol., 61, S14, 10.1016/j.jhep.2014.06.035 · DOI · Paper page
- Shrivastava, 2016, Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis, Hepatol. Int., 10, 937, 10.1007/s12072-016-9733-6 · doi:10.1007/s12072-016-9733-6
- Hannibal, 2017, Deficiency in plasmacytoid dendritic cells and type I interferon signalling prevents diet-induced obesity and insulin resistance in mice, Diabetologia, 60, 2033, 10.1007/s00125-017-4341-0 · DOI · Paper page
- Roh, 2014, Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis, Hepatology, 60, 237, 10.1002/hep.26981 · DOI · Paper page
- Mitsumoto, 2017, Time-course microarrays reveal early activation of the immune transcriptome in a choline-deficient mouse model of liver injury, Life Sci., 184, 103, 10.1016/j.lfs.2017.07.009 · DOI
- Wieser, 2016, Adipose type I interferon signalling protects against metabolic dysfunction, Gut
- Kumari, 2016, IRF3 promotes adipose inflammation and insulin resistance and represses browning, J. Clin. Invest., 126, 2839, 10.1172/JCI86080 · DOI · Paper page
- Wang, 2013, Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance, Am. J. Physiol. Endocrinol. Metab., 305, 10.1152/ajpendo.00505.2012 · DOI · Paper page
- Alzaid, 2016, IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans, JciInsight, 1
- Qiao, 2017, Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease, Metabolism
- Wang, 2014, Interferon regulatory factor 3 constrains IKKbeta/NF-kappaB signaling to alleviate hepatic steatosis and insulin resistance, Hepatology, 59, 870, 10.1002/hep.26751 · DOI · Paper page
- Eguchi, 2013, Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization, Diabetes, 62, 3394, 10.2337/db12-1327 · DOI · Paper page
- Wang, 2013, Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice, Hepatology, 58, 603, 10.1002/hep.26368 · DOI · Paper page
- Csak, 2011, Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice, Hepatology, 53, 1917, 10.1002/hep.24301 · DOI
- Ilan, 2012, Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis, World J. Gastroenterol., 18, 2609, 10.3748/wjg.v18.i21.2609 · DOI · Paper page
- Enomoto, 2001, Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin, Alcohol Clin. Exp. Res., 25
- Miura, 2013, Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice, Hepatology, 57, 577, 10.1002/hep.26081 · DOI · Paper page
- Kawai, 2007, TLR signaling, Semin. Immunol., 19, 24, 10.1016/j.smim.2006.12.004 · DOI · Paper page
- Jialal, 2014, Toll-like receptor status in obesity and metabolic syndrome: a translational perspective, J. Clin. Endocrinol. Metab., 99, 39, 10.1210/jc.2013-3092 · DOI · Paper page
- O'Neill, 2008, When signaling pathways collide: positive and negative regulation of Toll-like receptor signal transduction, Immunity, 29, 12, 10.1016/j.immuni.2008.06.004 · DOI · Paper page
- Fujihara, 2003, Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex, Pharmacol. Ther., 100, 171, 10.1016/j.pharmthera.2003.08.003 · DOI · Paper page
- Spruss, 2009, Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice, Hepatology, 50, 1094, 10.1002/hep.23122 · DOI · Paper page
- Csak, 2011, Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice, Am. J. Physiol. Gastrointest. Liver Physiol., 300, 10.1152/ajpgi.00163.2009 · DOI · Paper page
- Poggi, 2007, C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet, Diabetologia, 50, 1267, 10.1007/s00125-007-0654-8 · DOI · Paper page
- Szabo, 2005, Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4, Alcohol Clin. Exp. Res., 29
- Rivera, 2010, Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis, BMC Gastroenterol., 10, 52, 10.1186/1471-230X-10-52 · DOI · Paper page
- Ehses, 2010, Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet, Diabetologia, 53, 1795, 10.1007/s00125-010-1747-3 · DOI · Paper page
- Himes, 2010, Tlr2 is critical for diet-induced metabolic syndrome in a murine model, Faseb J., 24, 731, 10.1096/fj.09-141929 · DOI · Paper page
- Vijay-Kumar, 2007, Deletion of TLR5 results in spontaneous colitis in mice, J. Clin. Invest., 117, 3909
- Letran, 2011, TLR5-deficient mice lack basal inflammatory and metabolic defects but exhibit impaired CD4 T cell responses to a flagellated pathogen, J. Immunol. (Baltimore, Md. : 1950), 186, 5406, 10.4049/jimmunol.1003576 · DOI · Paper page
- Guo, 2015, Inflammasomes: mechanism of action, role in disease, and therapeutics, Nat. Med., 21, 677, 10.1038/nm.3893 · DOI · Paper page
- Szabo, 2015, Inflammasome activation in the liver: focus on alcoholic and non-alcoholic steatohepatitis, Clin. Res. Hepatol. Gastroenterol., 39, S18, 10.1016/j.clinre.2015.06.012 · DOI
- Wen, 2011, Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling, Nat. Immunol., 12, 408, 10.1038/ni.2022 · DOI · Paper page
- Eslam, 2016, Targeting IFN-: therapeutic implications, Expert Opin. Ther. Targets, 20, 1425, 10.1080/14728222.2016.1241242 · DOI
- Read, 2017, Zinc is a potent and specific inhibitor of IFN-lambda 3 signalling, Nat. Commun., 8
- Eslam, 2016, FibroGENE: a gene-based model for staging liver fibrosis, J. Hepatol., 64, 390, 10.1016/j.jhep.2015.11.008 · DOI · Paper page
- Li, 2017, Comprehensive variation discovery and recovery of missing sequence in the pig genome using multiple de novo assemblies, Genome Res., 27, 865, 10.1101/gr.207456.116 · DOI · Paper page
- Zhang, 2017, Transcriptome analyses reveal genes and pathways associated with fatty acid composition traits in pigs, Anim. Genet., 48, 645, 10.1111/age.12597 · DOI
- Liang, 2015, Liver injury and fibrosis induced by dietary challenge in the Ossabaw miniature Swine, PLoS One, 10, 10.1371/journal.pone.0124173 · DOI
Cited by
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationThe bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Hepatocytes demarcated by EphB2 contribute to the progression of nonalcoholic steatohepatitis
Xiao, Y., Batmanov, K., Hu, W., Zhu, K., Tom, A. Y., Guan, D., Jiang, C., Cheng, L., McCright, S. J., Yang, E. C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adc9653 · Cited by 69
“The induction of the type I IFN response in NAFLD livers has been attributed to excessive lipid species (52) or stimulation of stimulator of interferon response cGAMP interactor 1 (STING) that senses aberrant double-stranded DNA in the cytosol (53), but whether the induction of type I IFN plays a deleterious or benefi…”
BackgroundMartin, O. P., Wallace, M. S., Oetheimer, C., Patel, H. B., Butler, E. C., Wong, L. P., Huang, P., Elbaz, J., Costentin, C., Salloum, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02255-y · Cited by 45
Metadata
- Authors
- Møhlenberg, M., Terczynska-Dyla, E., Thomsen, K. L., George, J., Eslam, M., Grønbæk, H., & Hartmann, R.
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 124
- Pages
- 154519
- ISSN
- 1043-4666 (ISSN-L)
- OpenAlex
- W2888229165
- Cited by
- 50
- References
- 16
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of IFN in the development of NAFLD and NASH. https://app.cochat.ai/papers/10.1016/j.cyto.2018.08.013
- The paper
- Møhlenberg, M., Terczynska-Dyla, E., Thomsen, K. L., George, J., Eslam, M., Grønbæk, H., & Hartmann, R. (2019). The role of IFN in the development of NAFLD and NASH. Cytokine. https://doi.org/10.1016/j.cyto.2018.08.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.